SELLAS Life Sciences shares are trading higher after the company announced it received FDA rare pediatric disease designation status for Galinpepimut-S in pediatric acute myeloid leukemia.
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences shares rose after the company received FDA rare pediatric disease designation for its drug Galinpepimut-S, aimed at treating pediatric acute myeloid leukemia.
October 15, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences' stock is trading higher following the FDA's rare pediatric disease designation for its drug Galinpepimut-S, which targets pediatric acute myeloid leukemia.
The FDA's rare pediatric disease designation is a significant regulatory milestone that can lead to market exclusivity and potential financial incentives. This positive news likely boosts investor confidence, leading to a short-term increase in SLS stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100